We prospectively evaluated the efficacy and safety of consolidation and maintenance therapy with lenalidomide (Len) after high-dose therapy with autologous peripheral blood stem cell transplantation (HDT-ASCT) for newly diagnosed multiple myeloma (NDMM) patients. Twelve patients (pts) were enrolled and received bortezomib based regimen as an initial induction therapy. For patients who responded to induction therapy, high-dose melphalan with auto-PBSCT was performed followed by Len (10 mg) maintenance therapy for two years. Patients who had not achieved very good partial response after auto-PBSCT received consolidation therapy with Len 25 mg and dexamethasone before maintenance therapy. The median age was 67-year-old. Response rate above very good partial response after maintenance therapies was 91.7%. Two-year progression-free survival and overall survival were 83.3% and 91.7%, respectively. Progressive disease was observed in 2 pts during maintenance therapy. The grade 4 thrombocytopenia was observed in 2 pts. The grade 3–4 non-hematologic AEs were followings: skin rash in 3 pts and liver dysfunction one patient during maintenance therapy. These results suggest that Len consolidation and maintenance therapy are effective for NDMM patients, but early recurrence during maintenance therapy and adverse events of Len should be paid attention. More effective and safer maintenance therapy should be established.